Trial-by-gene · ROS1
Active trials enrolling ROS1 fusion-positive NSCLC
Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.
ROS1-fusion NSCLC trials focus on (1) repotrectinib post-crizotinib / -entrectinib resistance (G2032R covered), (2) next-generation ROS1 inhibitors with deep CNS penetration, and (3) 1L positioning of repotrectinib vs entrectinib.
See the ROS1 cheat sheet.
Browse the live listing
Search ClinicalTrials.gov for actively recruiting NSCLC trials with ROS1-directed interventions.
Open ClinicalTrials.gov listingSource: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.
Representative trial phases and designs
Phase I/II, post-TKI
Repotrectinib TRIDENT-1 expansion; novel ROS1 inhibitors.
Phase III, 1L
Direct comparisons among ROS1 TKIs in TKI-naive patients (limited so far).
Frequently asked questions
- How rare is ROS1 fusion-positive NSCLC?
- About 1-2% of NSCLC. The rarity makes trial accrual slower; broad NGS testing helps catch eligible patients.